Page 9 - மைய மருந்துகள் தரநிலைகள் கட்டுப்பாடு ஆர்கநைஸேஶந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

The antibody cocktail (casirivimab and imdevimab) is indicated for restricted use in emergency situation for the treatment of mild to moderate COVID-19 in patients who are at high risk of severe COVID-19.The first batch of the antibody cocktail (casirivimab and imdevimab), developed by the Roche Group, is now available in India while a second batch will be made available by mid-June. In total they can potentially benefit 200,000 patients as each of the 100,000 packs that will be available in India offers treatment for two patients. Cipla will distribute the product across the country. The drug will be available through leading hospitals and Covid treatment centers. Drug firm Roche India recently received approvals for the Emergency Use Authorisation (EUA) from the Central Drugs Standards Control Organisation (CDSCO) for the antibody cocktail to be used in treatment of the Coronavirus infection. It has also received a EUA in the US and several EU countries.

South africaUnited statesRoche groupCentral drugs standards control organisationRoche indiaEmergency use authorisationNorth americaCapital marketHealth sciencesAntiviral drugsCovid 19 drug developmentMonoclonal antibodiesOccupational safety and healthCasirivimab imdevimabHoffmann la rocheCovid 19